author-photo

L. E. Abrey

Hoffmann-La Roche

85

Papers

4290

Citations

Citation Trend

Filter By

Papers (65) Sort By

Journal Conference Others

Survival in elderly glioblastoma patients treated with bevacizumab-based regimens in the United States

2018 Neuro-Oncology Practice
Show All
- Source
- Cite
- Save
Citations (8)
Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (40)
Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo

2018 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (12)
CNS Anticancer Drug Discovery and Development: 2016 conference insights

2017 CNS oncology
Show All
- Source
- Cite
- Save
Citations (7)
Diffusion MRI phenotypes predict overall survival benefit from anti-VEGF monotherapy in recurrent glioblastoma: Converging evidence from phase II trials

2017 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (39)
NIMG-31. RESIDUAL ENHANCING TUMOR VOLUME IS A STRONG PROGNOSTIC BIOMARKER FOR SURVIVAL IN BOTH NEWLY DIAGNOSED AND RECURRENT GBM REGARDLESS OF THERAPY: EVIDENCE FROM 1,535 PATIENTS IN SINGLE AND MULTICENTER TRIALS

2016 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (0)
Radiologic progression types are treatment specific: An exploratory analysis of a phase 3 study of bevacizumab plus radiotherapy plus temozolomide for patients with newly diagnosed glioblastoma (AVAglio).

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
What is the role of whole brain radiation therapy (WBRT) and high-dose cytarabine (Ara-C) as consolidation treatment after initial chemotherapy for primary CNS lymphoma (PCNSL)?

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio

2016 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (33)
The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab

2016 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (44)